CoreBone has developed, and is distributing, bioactive, coral-based bone graft material that provides a natural alternative to human and animal-derived (bovine, porcine) bone grafts.

The Technology

CoreBone has developed a highly bioactive, strong, and resorbable bone graft material. The patented technology embeds bioactive minerals (e.g., silicium) into the skeleton of corals during their growth process to accelerate healing and provide better connectivity. It offers the same bonelike qualities as organic material (human/animal derived) without the associated risks.

The Advantages

CoreBone’s strictly controlled growing environment in its coral farm preserves the coral’s natural, bonelike properties.

CoreBone’s coral-based material offers —

  • Similar qualities to human (allograft) bone, but derived from coral
  • Better remodeling than bovine products (no heat treatment required); see more in Background & Market
  • Attractiveness to growing religious and vegetarian segments
  • Competitive pricing
  • Approved for dental and orthopedic implants

The Founding Team

Ohad Schwartz Corebone

CoreBone CEO Ohad Schwartz (left) speaks with Scot Dodd of CR Current during a Trendlines Medical U.S. Road Show event in Michigan.

  • Ohad Schwartz, CEO & Co-Founder: Former CEO, Vaica Medical (medication management); CEO and co-founder, Aspect AI (MRI technologies); VP, TAMI 4
  • Prof. Itzhak Binderman, DMD, Co-Founder: Internationally recognized researcher in bone biology and dentistry; former head of Dental Dept. and Hard Tissue Laboratory, Sourasky Medical Center, Tel Aviv; School of Dental Medicine and Dept. of Bioengineering, Tel Aviv Univ.; senior researcher, Hospital for Special Surgery, New York

Trendlines’ directors: Nitza Kardish, Steve Rhodes


Stage: Revenue; sales in France, Poland, Israel
Founded: December 2011
Investors: The Trendlines Group; private investors in Israel, United States, and Singapore; founders
IP: U.S. patent (2015) and Israeli patent; EU patent pending

September 2017 update
CoreBone continues to expand sales. CoreBone developed a natural alternative to human and animal-derived bone grafts. The Company’s bone-like graft is made from the pure mineral exoskeleton of corals grown in a controlled environment and using a patented process.

“We presented our products at the largest dental show in Cologne, Germany,” says CEO Ohad Schwartz, ” and received very positive feedback from visitors and distributors. Opinion leaders confirmed that the CoreBone material compares to the gold standard for dental bone graft. However, since we are not a bovine-derived product, our material is better replaced by bone (remodeling ) and appeals to segments (and countries) that are opposed to using human or animal derivatives.

“We are currently selling in France, Poland,  Israel, and soon Romania, and have received distribution requests from other countries — and doctors — around the world. We signed a distribution agreement with a top dental implant company and give regular training sessions to customers and distributors. In this month alone, we are shipping 1,000 units.”

CoreBone earned CE mark and AMAR approval (from Israel’s Ministry of Health) to market its products in Israel and worldwide to the dental and orthopedic markets.


  • March 2017 Product launch
  • January 2017: Approval from Israel’s Ministry of Health
  • Distribution agreements in Israel, France, Poland, Romania, and with a leading dental implant company
  • October 2016: CE mark class III
  • Ongoing sales in Israel and Europe
  • Ongoing studies with leading hospitals
  • Highly positive feedback from KOLs: “Just like Bioss” (the gold standard, global leader, bovine-derived)

In the Media

Background & Market

Today, implants are used more and more in dental and orthopedics. In many cases, bone is insufficient, and bone grafts stimulate the growth of new bone to support and anchor the implant. Most bone graft materials in the market are derived from human and animal bone and carry the risk of disease and rejection. *Furthermore, bovine-derived products hardly remodel due to the heat treatment that is essential to reduce viral risks. Synthetic materials, a fast-growing segment, lack strength.

Bone grafts from human and animal origin are in decline due to their associated risks. The synthetic bioactive product share is growing as the market seeks alternatives. The global market for orthopedic bone graft substitutes is expected to reach $3.4 billion by 2022 (Allied Market Research). According to Transparency Market Research, the global dental membrane and bone graft substitutes market is expected to reach $922.6 million by 2024.


CEO Ohad Schwartz interviewed on Start-Up Stadium

CEO Ohad Schwartz interviewed on ILTV.

CEO Ohad Schwartz presents at the Trendlines Showcase.

CoreBone's biocactive bone graft material

CoreBone's coral-based biocactive bone graft material


Ohad Schwartz, CEO

CoreBone logo card

Font Resize